Optovue Global Information

Optovue is a progressive ophthalmic medical device company focused on advancing optical coherence tomography (OCT) technology. The company is dedicated to working with eye care professionals and clinical researchers to lead the development and commercialization of high-speed OCT and OCT angiography (OCTA), used to facilitate the visualization and management of eye diseases, many of which may lead to permanent blindness. The Optovue team is comprised of seasoned professionals experienced in design, development, production, marketing, and sales of ophthalmic devices with the common goal of providing our customers and their patients the best products and services possible. The company is assisted by a Scientific and Medical Advisory Board composed of leaders in advanced OCT technology and ocular disease treatment. Optovue pioneered the clinical use of OCT technology that resulted in the first FDA cleared Fourier-domain (spectral domain) OCT system, the RTVue®. The ultra-high speed, high resolution SD-OCT provides advanced ocular imaging capabilities that offer physicians significant benefits in helping to diagnose and manage patients suffering from macular degeneration, diabetic retinopathy, glaucoma and other macular diseases, as well as anterior segment diseases. The company expands the frontiers of OCT innovation and ophthalmic medical diagnostic imaging to improve the lives of patients. To date, Optovue has received regulatory clearances for: • RTVue OCT - Oct. 2006 • iVue portable OCT - April 2010 • Avanti Widefield OCT - April 2012 • Total Corneal Power, Oct. 2011 • iCam digital fundus camera - Jan. 2013 • iFusion combination OCT and fundus camera - July 2013 • iScan, software-assisted OCT – Sept. 2014 • AngioVue Imaging System – February 2016 • AngioAnalytics – June 2018